Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02072018 · ClinicalTrials.gov registry record · Phase 1

Peyronie's Disease Treatment Protocol

A Phase 1 study of Peyronie's Disease, sponsored by Hybrid Medical.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT02072018 is a Phase 1 study of Peyronie's Disease that has completed, run by Hybrid Medical. The registered enrollment target is 22 participants, below the 186-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02072018, a Phase 1 study of Peyronie's Disease, has completed, sponsored by Hybrid Medical.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.

Conditions Studied

Peyronie's Disease

Interventions

  • DRUG Placebo
  • DRUG H-100

Study Locations (1)

Minnesota

  • North Memorial Medical Center - Robbinsdale

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2013-06
Est. Completion 2013-12
Phase Phase 1

Sponsor

Hybrid Medical

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02072018

The ClinicalTrials.gov registry entry for NCT02072018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (88% lower). The listed sponsor is Hybrid Medical, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peyronie's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02072018 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02072018 about?

NCT02072018 is a clinical study titled "Peyronie's Disease Treatment Protocol". Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.

What is the current status of trial NCT02072018?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2013-06. Estimated completion is 2013-12.

What conditions does trial NCT02072018 study?

This clinical trial studies the following conditions: Peyronie's Disease.

What interventions are being tested in trial NCT02072018?

The interventions under investigation include: Placebo (DRUG), H-100 (DRUG).

Who is sponsoring clinical trial NCT02072018?

This trial is sponsored by Hybrid Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02072018 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Peyronie's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Peyronie's Disease

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.